Next Generation Diabetes Therapy and Drug Delivery Technologies

Next Generation Diabetes Therapy and Drug Delivery Technologies

Global Diabetes Epidemic Adds Urgency to R&D Initiatives, Inhalable and Transdermal Delivery on Upward Trajectory

RELEASE DATE
30-Mar-2016
REGION
Global
Research Code: D6D9-01-00-00-00
SKU: LS00154-GL-TR_17036
$4,950.00
In stock
SKU
LS00154-GL-TR_17036
$4,950.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

Diabetes has exhibited dramatic increases during the past decade, registering a global prevalence of 9% among adults aged 18 years and older, and is projected to be the 7th-leading cause of death by 2030. The most popular treatment for type 1 diabetes mellitus (T1DM) is multiple daily insulin (MDI) injections. However, researchers globally are working on both the development of novel drugs to fight diabetes, and on the design of novel insulin delivery systems. These delivery systems mostly via use oral and pulmonary routes using nanocarrier-based delivery systems, as well as transdermal delivery to through patches and infusion pumps, which aim to improve the quality of life of diabetic patients.

An important new business model is emerging between large pharmaceutical/biopharmaceutical companies and medical devices firms with the objective of accelerating the delivery of novel therapeutic systems to the industry. Medical device companies and drug manufacturing companies sign long-term partnership agreements to combine their drug delivery devices with the most-active diabetes therapeutics, thereby bringing down the operational costs and saving a significant amount of time during the process.

This research service (RS) examines the current landscape and new trends in diabetes drug delivery, focusing on:

Technology trends and capability
Stakeholder activities, influence, industry initiatives, and applications targeted
Industry initiatives, regulation, and standardization approaches for tackling challenges
Technology benchmarking for specific applications

An appendix is included, comprising lists of the major participants in the study and the most notable patents in the field.

Table of Contents

1.1 Research Scope: Cutting-edge Tech Convergence

1.2 Research Scope: Next Generation Technologies

1.3 Research Methodology: The Approach Core Value

1.4 Key Findings: Urgent Need to Address a Critical Global Concern

1.5 Key Findings: Different New Approaches Converging to Diabetes Care

1.6 Key Findings: Multidisciplinary Interaction as the Key Instrument

2.1 Industry Value Chain: Key Enabling Technologies Driving Innovation Business Model

2.2 Diabetes Drug Delivery Market Impact: CAGR of 12.7% from 2020 to 2025

2.3 Diabetes Drug Delivery Market Impact: Emerging Markets Gaining Attention for the Next Decade

2.4 Diabetes Drug Delivery Regional Revenue Growth: The Perfect Niche for Each Region for Global Success

2.5 Diabetes Drug Delivery Business Facts: Translation Medicine as Mandatory

3.1 Diabetes Drug Delivery Innovation Fields: The Scenario for Big Technology Synergy

3.2 Diabetes Drug Delivery Innovation in Pharma/Biotech: Novel Therapeutics in the Field

3.3 Diabetes Drug Delivery Innovation in Medtech: Complementing Devices for More Efficient Therapy

3.4 Diabetes Drug Delivery Innovation in Synertech: Leveraging Technology Advances for Smart Therapy

3.5 Diabetes Drug Delivery Innovation Model: The Right Pathway in the Precision Medicine Era

3.6 Diabetes Drug Delivery Innovation Model: New Innovation Strategies and Cooperation Frameworks

3.7 Diabetes Drug Delivery Development Pipeline: Time to Market Averages for Each Approach

3.8 Diabetes Drug Delivery Development Pipeline: Cascade Effect on the Healthcare Systems Efficiency

4.1 Pharma/Biotech: Insulin Human Inhalation Powder

4.2 Pharma/Biotech: TANZEUM (albiglutide)

4.3 Pharma/Biotech: XIGDUO XR

4.4 Pharma/Biotech: Xultophy (IDegLira)

4.5 Pharma/Biotech: Smart Insulin

4.6 Pharma/Biotech: Bile Acid Microcapsules

4.7 Medtech: FreeStyle Libre Flash Glucose Monitoring

4.8 Medtech: Smart Contact Lenses for Glucose Monitoring

4.9 Medtech: Microneedle Pill with Hollow Needles

4.10 Medtech: Autoantibody Measuring Microchip

4.11 Medtech: SmartGuard GlucoSitter

4.12 Medtech: iLet Bihormonal Bionic Pancreas

4.13 Medtech: ITCA 650

4.14 Medtech: G-Pen Mini™ Glucagon Injection

4.15 Synertech: Glucose Nanosensors

4.16 Synertech: Cell Reprogramming via Nanotechnology

4.17 Synertech: 3D Bioplotted Hydrogel Scaffolds

4.18 Synertech: Spherical Nucleic Acids

4.19 Synertech: Engineering ß-Cell Replacement Therapy

4.20 Synertech: Glucose-responsive Insulin-producing Cells

4.21 Other Innovative Technologies to Watch: Combining Smart Devices with Therapeutics

4.22 Other Innovative Technologies to Watch: Novel Cell-based Platforms Targeting Diabetes Care

4.23 Diabetes eHealth Applications to Follow: Internet of Therapy Approach

5.1 Multi-criteria Approach for Benchmarking: Introducing Analytical Hierarchy Process Approach

5.2 Multi-criteria Approach for Benchmarking: Selected Criteria for Assessment

5.3 Multi-criteria Approach for Benchmarking: Level 0 Criteria

5.4 Multi-criteria Approach for Benchmarking: Level 1 Criteria – Research and Development

5.5 Multi-criteria Approach for Benchmarking: Level 1 Criteria – Financial Support and Funding

5.6 Multi-criteria Approach for Benchmarking: Level 1 Criteria – Market Landscape

5.7 Multi-criteria Approach for Benchmarking: Level 2 Criteria

5.8 Multi-criteria Approach for Benchmarking: Graphical Final Results

5.9 Multi-criteria Approach for Benchmarking: Final Analysis

5.10 R&D Benchmarking: Framework for Innovations Assessment

5.11 R&D Benchmarking: Competitive Differentiation as the Basic Rule

5.12 R&D Benchmarking: Time to Market Leading Focus of Main Innovations

5.13 R&D Benchmarking: Several Innovations Addressing Multiple Business Goals

5.14 R&D Benchmarking: The Crucial Need to Support Research and Development

5.15 Final Remarks: High Pressure over Diabetes Care

6.1 Intellectual Property: Over 280,000 Patents Covered during the Past Three Decades

6.2 Intellectual Property: Sustained Interest in Diabetes Care Publishing Trends

6.3 Intellectual Property: Leading Pharmaceutical and Medical Devices Companies at the Front

6.4 Intellectual Property: Distribution by Region and Patent Offices Worldwide

7.1 Key Industry Influencers

7.1 Key Industry Influencers (continued)

7.1 Key Industry Influencers (continued)

7.2 Key Academic Influencers

7.2 Key Academic Influencers (continued)

7.3 Intellectual Property Sources

7.4 Key Granted Patents

7.4 Key Granted Patents (continued)

7.4 Key Granted Patents (continued)

7.4 Key Granted Patents (continued)

7.4 Key Granted Patents (continued)

7.4 Key Granted Patents (continued)

7.4 Key Granted Patents (continued)

Legal Disclaimer

8.1 The Frost & Sullivan Story

8.2 Value Proposition: Future of Your Company & Career

8.3 Global Perspective

8.4 Industry Convergence

8.5 360º Research Perspective

8.6 Implementation Excellence

8.7 Our Blue Ocean Strategy

Related Research
Diabetes has exhibited dramatic increases during the past decade, registering a global prevalence of 9% among adults aged 18 years and older, and is projected to be the 7th-leading cause of death by 2030. The most popular treatment for type 1 diabetes mellitus (T1DM) is multiple daily insulin (MDI) injections. However, researchers globally are working on both the development of novel drugs to fight diabetes, and on the design of novel insulin delivery systems. These delivery systems mostly via use oral and pulmonary routes using nanocarrier-based delivery systems, as well as transdermal delivery to through patches and infusion pumps, which aim to improve the quality of life of diabetic patients. An important new business model is emerging between large pharmaceutical/biopharmaceutical companies and medical devices firms with the objective of accelerating the delivery of novel therapeutic systems to the industry. Medical device companies and drug manufacturing companies sign long-term partnership agreements to combine their drug delivery devices with the most-active diabetes therapeutics, thereby bringing down the operational costs and saving a significant amount of time during the process. This research service (RS) examines the current landscape and new trends in diabetes drug delivery, focusing on: Technology trends and capability Stakeholder activities, influence, industry initiatives, and applications targeted Industry initiatives, regulation, and standardization approaches for tackling challenges Technology benchmarking for specific applications An appendix is included, comprising lists of the major participants in the study and the most notable patents in the field.
More Information
No Index No
Podcast No
Author Cecilia Van Cauwenberghe
WIP Number D6D9-01-00-00-00
Keyword 1 Diabetes Therapy
Keyword 2 Next Generation Diabetes Therapy
Keyword 3 Drug Delivery Technology
Is Prebook No